Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT CAPTIONS - LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2023

Accounts payable and accrued expenses consisted of the following at September 30, 2023 and December 31, 2022 (in thousands):


	September 30, 2023		December 31, 2022
Accounts payable:
Clinical and regulatory expenses	$	680	$	361
Professional fees		723		626
Selling expenses		1,542		1,363
Manufacturing costs		770		650
Non-employee director compensation		693		484
Other vendors		397		301
Total accounts payable		4,805		3,785
Accrued interest payable, related parties		590		144
Accrued interest payable		2,726		2,381
Accrued expenses:
Payroll expenses		1,310		1,263
Government rebates and other rebates		5,131		5,536
Due to customers		844		—
Other accrued expenses		879		440
Total accrued expenses		8,164		7,239
Total accounts payable and accrued expenses	$	16,285		13,549

Other current liabilities consisted of the following at September 30, 2023 and December 31, 2022 (in thousands):


	September 30, 2023		December 31, 2022
Trade discount	$	3,300	$	1,200
Unearned revenue (a)		10,000		10,000
Other current liabilities		1,100		1,717
Total other current liabilities	$	14,400	$	12,917

(a) Represents the fee payable to Telcon pursuant to the distributor agreement. See Note 3 for additional details.

Other long-term liabilities consisted of the following at September 30, 2023 and December 31, 2022 (in thousands):


	September 30, 2023		December 31, 2022
Trade discount	$	17,205	$	21,682
Other long-term liabilities		35		32
Total other long-term liabilities	$	17,240	$	21,714